Ligand Pharma-Roche CVRLGNDZPreferred / convertible
13F holders, Q1 2026 (March 31)1holders
0new positions
0sold out
$0.00avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Ligand Pharma-Roche CVR (LGNDZ) in their 13F filings, unchanged from Q4 2025. 0 opened new positions and 0 sold out. The largest holder was Ancora Advisors LLC ($16).
- Company
- Ligand Pharma-Roche CVR
- CUSIP
- 53220K215
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Ancora Advisors LLC | — | No change | 12,000 | $16 |
"% of holder's portfolio" is LGNDZ's weight in each manager's 13F, not the share of Ligand Pharma-Roche CVR the manager owns.